18 results
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Incidence: common in APL ... Triggers: ATRA treatment ... common • Imaging: CXR ... - pulmonary opacities ... sepsis), PE, DAH, CHF
Hyperviscosity Syndrome - Causes and Treatment

 - Waldenstrom macroglobulinemia (most common) / Plasmapheresis 
 - Multiple
Syndrome - Causes and Treatment ... hyperleukocytosis (AML ... Phlebotomy - MH/CCF ... Differential #Diagnosis #Treatment
Heart Failure (HFrEF) Treatment - GDMT for stage C 

For patients with Heart Failure with REDUCED
Failure (HFrEF) Treatment ... recommended by the ACC ... /ambcarerx #CHF ... #HFrEF #Pharmacology ... #Management #Treatment
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
: 33% • Treatment ... : Age>60, CKD, CHF ... fluid balance, and CXR ... with pulmonary ... : No • Treatment
Heart failure with Reduced Ejection Fraction (HFrEF)
Clinical Presentation
1. Typical symptoms: dyspnea, orthopnea paroxysmal noctumal dyspnea, fatigue,
→ no signs of CXR ... endomyocardial biopsy Pharmacology ... : • ACE Inhibitors ... management #cardiology #pharmacology ... #sCHF
Severe Heart Failure & Cardiogenic Shock - Management Checklist 
Evaluation 
 - EKG & echocardiography
in cardiogenic pulmonary ... hypoperfusion, no pulmonary ... Revascularization, treatment ... NSAlDs, ACE-inhibitors ... #Checklist #CHF
On the left another patient with alveolar edema at admission, which resolved after treatment.
When you scroll
resolved after treatment ... distribution of pulmonary ... Clinical #Radiology #CXR ... #CHF #Alveolar ... #Pulmonary #Edema
It is important to recognize Acute Decompensated Heart Failure (ADHF) as more than just simply a
with presence of pulmonary ... & Dry) is the treatment ... & Dry” is the treatment ... #heartfailure #chf ... icu #clinical #pharmacology
Veltassa (Patiromer) 
MECHANISM: Potassium Binder 
INDICATION: Treatment of Hyperkalemia 
FORMULATION: Powder for oral suspension 
DOSING: 8.4
INDICATION: Treatment ... patients with CKD, HF ... ACE inhibitors, ... #Hyperkalemia #Pharmacology
Myelodysplastic Syndromes (MDS)

What?
Myelodysplastic syndromes are a group of disorders caused by blood cells that are poorly
transformation to AML ... factor (GCSF) treatments ... marrow studies Treatment ... progression to AML ... factors (examples: G-CSF